The "other" Charts thread

action hasn't been good But I don't have to tell you guys that.
Although OPKO technically in a long boring 10 month uptrend off the lows of the year..
Close to breaking it though.. see if we can bounce here
(really a stretch to find a positive in the chart..  )


Opko Health Inc (NASDAQ:OPK) is a $5 billion biotech company involved in medical testing and medications that are focused on diagnostics and pharmaceuticals. This biotech company develops treatments for secondary hyperparathyroidism, and recently finished the patient recruitment for a Phase III trial against insufficiency in Vitamin D. They are engaged in the development and commercialization of pharmaceutical vaccines, diagnostic technologies, and imaging systems.

OPK also have an FDA Approved drug that is set to launch by the end of the year, called Rayaldee. Opko has partnered with with a dialysis company in exchange for milestone payments and a royalties on Rayaldee (double digit tiered royalties).

Rayaldee aims to attack chronic kidney disease (CKD) which OPK figures has a 26 million patient population in the US alone. Although, 26 million is the patient population for all forms of CKD, whereas Rayaldee is only approved to treat a subset of those patients.

OPKO Health was was just listed on the Nasdaq a few months ago. The Revenue for OPKO is up 3X over 2015, and for the full year it will be just over a billion. Much of the revenue is coming from their purchase of Bio-Reference Laboratories. It is a cash flowing lab bought last year and is the third largest diagnostics lab in the US. This Biotech company is hoping to roll out more Diagnostics products, including the 4kscore test for prostate cancer. Then, leveraging the Bio-Reference sales force with their new Claros diagnostics testings machine system.

Over the last 6 months their have been 163 Insider buys and no sells. Revenue is up 3x over 2015. The FDA has already approved its drug, launching Q4 2016. A buyout is very possible because of its growth and bullish long-term outlook. The fact OPK stock has been cut in half since its high last year makes it that much more attractive. CEO Phillip Frost must think shares are attractive too, with him loading up on 302,000 in the last six months.



they stole my chart but its a decent article so.. OK




bnlfinance.com/2016/10/20/opko-health-inc-opk-attractive-biotech-acquisition-target/